RxDoctor Payments Data

Yu Zhu, MD

Neurology · Tacoma, WANPI 1134126170

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 57 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$455
  • AbbVie$172
  • AstraZeneca$112
  • Novartis$100
  • EMD Serono, Inc.$92
  • Alnylam Pharmaceuticals Inc.$71
  • plus $418 from 13 others

What the payments were for

  • Speaking & faculty fees$463%
  • Food & beverage$1,34595%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 65th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$55,726
Medicare patients
202
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$207,578
Avonex Pen (4 Pack)Interferon Beta-1a11$88,387
UbrelvyUbrogepant36$40,028
Aimovig AutoinjectorErenumab-Aooe40$37,239
Nurtec OdtRimegepant Sulfate13$23,668
Emgality PenGalcanezumab-Gnlm14$21,496
QuliptaAtogepant12$12,591
Gabapentin192$5,036
Pregabalin45$4,886
Mycophenolate Mofetil31$4,048
Carbamazepine ErCarbamazepine13$2,398
Carbidopa-LevodopaCarbidopa/Levodopa35$2,329
Pyridostigmine Bromide39$2,093
Sumatriptan Succinate50$1,650
Carbidopa-Levodopa ErCarbidopa/Levodopa32$1,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$172$52,61948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 418 neurology providers in Washington.

Other neurology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →